Analysis of clinical efficacy of tiotropium bromide combined with salmeterol/fluticasone propionate on moderate-severe COPD at stable stage

Objective: To explore the clinical effect of drug combination therapy on moderate-severe COPD at stable stage. Methods: 120 patients with moderate-severe COPD at stable stage were randomly divided into the control group and the observation group. The patients in the control group were given salmeterol / fluticasone propionate,and those in the observation group were given tiotropium bromide additionally on basis of the control group. Results: The pulmonary function( FVC,FEV1,FEV1 % Pred and FEV1 / FVC) of patients in the observation group were significantly improved after treatment. Compared with that in the same group before treatment and in the control group after treatment,there was significant difference( P 0. 05). 6MWT in the two groups was significantly extended than that in the same group before treatment( P 0. 05). The score of each factor in the SGRQ questionnaire scale of the two groups after treatment was significantly lower,and there was significant difference in the score before and after treatment( P 0. 05). Conclusions: The application of tiotropium bromide combined with salmeterol / fluticasone propionate to moderate-severe COPD at stable stage can effectively improve the respiratory function and the living quality of patients.